Changes in Echogenicity and Muscle Stiffness in Elastography After Botulinum Toxin Injection a Spastic Muscle

Changes in Echogenicity and Muscle Stiffness in Elastography After Botulinum Toxin Injection a Spastic Muscle - A Monocentric Study

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02550509

Enrollment

Registered

2015-09-15

Start date

2013-11-30

Completion date

2016-06-30

Last updated

2016-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

stroke, Botulinum toxin, Muscle alterations

Brief summary

Muscle alterations and modifications passive biomechanical properties that occur on a spastic muscle contribute to functional disorders involved in spasticity. Botulinum toxin (TB) A is the reference treatment of the focused spasticity, and muscle source structural and biomechanical changes, very little studied in humans, especially since it is not one possibility of easily and reliably paraclinical assessment injections consequences.

Interventions

DEVICEultrasound echogenicity

ultrasound echogenicity to patient with stroke

DEVICEelastography

elastography to patient with stoke

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* A first stroke older than nine months (acute phase and subacute stroke). * Hemiplegia cerebral vascular following this stroke. * Hemiplegia with an overall motor deficit plegic lower limb muscle testing level less than or equal to 3 and associating a localized spasticity lower plegic member, on the plantar flexors, assessed by the upper Ashworth Scale or equal to 1 with an injection of botulinum toxin indication of the sural triceps. * written consent.

Exclusion criteria

* Old stroke with motor impairment of the lower limb in the chronic stage. * Concomitant muscle disease (eg myopathy, myositis ...). * Patients who already received a botulinum toxin injection into the gastrocnemius muscles. * Subjects with defibrillator

Design outcomes

Primary

Measure	Time frame	Description
Change in muscular trophism	from baseline to 1 year	Change in muscular trophism treated by botulinum toxin. Muscular trophism determined by a combined endpoint assessment of muscular echogenicity following scale Heckmatt I to IV, the measurement of the thickness in mm and angle pennation fascicular of medial and lateral gastrocnemius muscles to measured with an ultrasound scanner

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026